Browse hierarchy Clinical Chemistry (CH) Subpart B — Clinical Chemistry Test Systems 21 CFR 862.1665 Product Code JGS K070104 — PROLYTE ELECTROLYTE ANALYZER
PROLYTE ELECTROLYTE ANALYZER
K070104 · Diamond Diagnostics, Inc. · JGS · May 7, 2008 · Clinical Chemistry
Device Facts
Record ID K070104
Device Name PROLYTE ELECTROLYTE ANALYZER
Applicant Diamond Diagnostics, Inc.
Product Code JGS · Clinical Chemistry
Decision Date May 7, 2008
Decision SESE
Submission Type Traditional
Regulation 21 CFR 862.1665
Device Class Class 2
Indications for Use
The proLYTE Electrolyte Analyzer is designed for clinical laboratory use by laboratory professionals to assess the levels of Sodium, Potassium, and Chloride found in whole blood, serum, plasma, and urine of patients. The analysis is performed in-vitro, and neither the analyzer nor any of its components come in contact with the patient. This analyzer is used by laboratory trained technicians in clinical laboratories to aid in the diagnosis and treatment of patients with electrolyte imbalance. These locations routinely conform to CLIA regulations, and conduct daily quality control programs. For In Vitro Diagnostic Use
Device Story
Automated, microprocessor-controlled analyzer; utilizes ion-selective electrodes (ISE) to measure sodium, potassium, and chloride levels in whole blood, serum, plasma, or prediluted urine. Operated by laboratory technicians in clinical settings; provides results in approximately 55 seconds for blood and 90 seconds for urine. Device features simple menu navigation; performs automatic 1-point calibration per measurement and scheduled 2-point calibrations. Output displayed on-screen and sent to printer/computer; stores up to 125 patient results and 20 QC results. Aids clinicians in diagnosing and managing renal, metabolic, and cardiovascular disorders by identifying electrolyte imbalances.
Clinical Evidence
Bench testing only. Precision evaluated via 40 replicates across matrices (whole blood, serum, plasma, urine) at low/high concentrations. Linearity confirmed via dilution studies across claimed ranges (R² ≥ 0.995). Method comparison performed against predicate device using patient samples (n=42-69 per matrix/analyte); results showed strong correlation. Analytical specificity tested against common interferents; interference noted for bromide, thiocyanate, and albumin at specific concentrations.
Technological Characteristics
Ion-selective electrode (ISE) technology. Flow-through glass tube (sodium) and neutral carrier ionophore membrane (potassium/chloride). Silver/silver chloride reference electrode. Microprocessor-controlled. Automated calibration. Standalone benchtop analyzer. Software-based automated analysis.
Indications for Use
Indicated for patients requiring assessment of Sodium, Potassium, and Chloride levels in whole blood, serum, plasma, or urine to aid in the diagnosis and treatment of electrolyte imbalance.
Regulatory Classification
Identification A sodium test system is a device intended to measure sodium in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of aldosteronism (excessive secretion of the hormone aldosterone), diabetes insipidus (chronic excretion of large amounts of dilute urine, accompanied by extreme thirst), adrenal hypertension, Addison's disease (caused by destruction of the adrenal glands), dehydration, inappropriate antidiuretic hormone secretion, or other diseases involving electrolyte imbalance.
Predicate Devices
Medica EasyLYTE (k000926)
Related Devices
K102959 — PROLYTE ELECTROLYTE ANALYZER · Diamond Diagnostics, Inc. · Jan 14, 2011
K961458 — AVL 9180 ELECTROLYTE ANALYZER · Avl Scientific Corp. · Jun 12, 1996
K121040 — SMARTLYTE ELECTROLYTE ANALYZER · Diamond Diagnostics, Inc. · Aug 30, 2012
Submission Summary (Full Text)
{0}
1
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY AND INSTRUMENT COMBINATION TEMPLATE
A. 510(k) Number:
k070104
B. Purpose for Submission:
New Device
C. Measurand:
Sodium, Potassium, Chloride
D. Type of Test:
Ion Selective Electrode
E. Applicant:
Diamond Diagnostics, Inc.
F. Proprietary and Established Names:
proLYTE Electrolyte Analyzer
G. Regulatory Information:
1. Regulation section:
21 CFR 862.1665 – Sodium Test System
21 CFR 862.1600 – Potassium Test System
21 CFR 862.1770 – Chloride Test System
2. Classification:
Class II
3. Product code:
{1}
JGS - Electrode, Ion Specific, Sodium
CEM – Electrode, Ion Specific, Potassium
CGZ – Electrode, Ion Specific, Chloride
4. Panel:
75 - Chemistry
## H. Intended Use:
1. Intended use(s):
See indications for use below.
2. Indication(s) for use:
The proLYTE Electrolyte Analyzer is designed for clinical laboratory use by laboratory professionals to assess the levels of Sodium, Potassium, and Chloride found in whole blood, serum, plasma, and urine of patients. The analysis is performed in-vitro, and neither the analyzer nor any of its components come in contact with the patient.
This analyzer is used by laboratory trained technicians in clinical laboratories to aid in the diagnosis and treatment of patients with electrolyte imbalance. These locations routinely conform to CLIA regulations, and conduct daily quality control programs.
For In Vitro Diagnostic Use
3. Special conditions for use statement(s):
For prescription use only
4. Special instrument requirements:
proLYTE Electrolyte Analyzer
## I. Device Description:
The proLYTE is an automated, microprocessor-controlled analyzer which utilizes ion-selective electrodes for the measurement of sodium, potassium and chloride in serum, plasma, whole blood and prediluted urine samples.
## J. Substantial Equivalence Information:
1. Predicate device name(s):
{2}
Medica EasyLYTE
2. Predicate 510(k) number(s):
k000926
3. Comparison with predicate:
| Similarities | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Measurement Method | Ion selective electrode | Ion selective electrode |
| Analytes measured | sodium, potassium, chloride | sodium, potassium, chloride |
| Sample matrix | Whole blood, plasma, serum, urine | Whole blood, plasma, serum, urine |
| Calibration | Automatic and on demand | Automatic and on demand |
| Differences | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Measuring range whole blood, serum, plasma | Na: 45-210 mmol/L, K: 1.5-12 mmol/L Cl: 45-210 mmol/L | Na: 80-200 mmol/L, Cl: 1-10 mmol/L K: 80-200 mmol/L |
| Measuring range urine | Na: 30-1020 mmol/L, K: 20-505 mmol/L Cl: 25-506 mmol/L | Na: 80-200 mmol/L, Cl: 1-10 mmol/L K: 80-200 mmol/L |
| Blood analysis time | 57 seconds | 55 seconds |
| Urine analysis time | 93 seconds | 90 seconds |
| QC storage | Normal, abnormal 20 each | Normal, low, high, 20 each |
## K. Standard/Guidance Document Referenced (if applicable):
None referenced
## L. Test Principle:
The proLYTE measures sodium, potassium and chloride in whole blood, serum, plasma, and urine, using ion selective electrode technology. The flow-through sodium electrode contains a glass tube, specially formulated to be sensitive to sodium ions. The flow-through potassium and chloride electrodes incorporate a neutral carrier ionophore membrane. The potential of each electrode is measured relative to a fixed, stable voltage established by the silver/silver chloride reference electrode. An ion selective electrode develops a voltage that varies with the concentration of the ion to which it responds. The relationship between the voltage developed and the concentration of the sensed ion is logarithmic.
{3}
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
Within run precision was calculated with results from three whole blood, serum, plasma, and urine samples for each analyte. The samples concentrations were at the low and high end of the measuring range and within the measuring range. The protocol called for running 40 replicates of each sample without calibration between measurements. The replicates were run consecutively in one day. Some of the samples had fewer replicates due to instrument errors. The results are summarized below.
Whole Blood
| | Na+ | K+ | Cl- | Na+ | K+ | Cl- | Na+ | K+ | Cl- |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mean | 114.6 | 2.27 | 51.3 | 139.5 | 3.91 | 91.1 | 162.6 | 6.15 | 120.7 |
| %CV | 0.9 | 1.7 | 2.0 | 0.8 | 1.5 | 0.9 | 0.6 | 1.4 | 0.9 |
| n | 39 | 39 | 39 | 39 | 39 | 39 | 39 | 39 | 39 |
Serum
| | Na+ | K+ | Cl- | Na+ | K+ | Cl- | Na+ | Cl- |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mean | 115.9 | 3.17 | 66.6 | 145.5 | 6.63 | 99.1 | 163.5 | 109.8 |
| %CV | 0.7 | 1.1 | 1.9 | 0.6 | 0.8 | 1.1 | 0.7 | 0.5 |
| n | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 |
Plasma
| | Na+ | K+ | Cl- | Na+ | K+ | Cl- | Na+ | K+ | Cl- |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mean | 114.2 | 2.77 | 46.4 | 139.6 | 3.87 | 80.4 | 161.8 | 6.53 | 113.4 |
| %CV | 0.9 | 1.9 | 2.0 | 0.7 | 0.8 | 0.9 | 0.6 | 1.0 | 0.9 |
| n | 34 | 34 | 34 | 34 | 34 | 34 | 34 | 34 | 34 |
Urine
| | Na+ | K+ | Cl- | Na+ | K+ | Cl- | Na+ | K+ | Cl- |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mean | 60.9 | 31.12 | 78.6 | 173.3 | 104.15 | 156.4 | 279.8 | 168.83 | 231.9 |
| %CV | 0.9 | 1.5 | 2.0 | 0.6 | 0.7 | 1.9 | 0.8 | 1.0 | 0.8 |
| n | 34 | 34 | 34 | 35 | 35 | 35 | 35 | 35 | 35 |
Total precision was calculated with results from three whole blood, serum, plasma, and urine samples for each analyte. The samples concentrations were at the low and high end of the measuring range and within the measuring range. The samples were measured twice each morning and twice each afternoon for ten consecutive days resulting in $n = 40$ replicates. One whole blood sample and three urine samples had $n = 39$ replicates due to instrument errors. The results are summarized below.
Whole Blood
{4}
| | Na+ | K+ | Cl- | Na+ | K+ | Cl- | Na+ | K+ | Cl- |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mean | 115.7 | 2.43 | 47.1 | 140.2 | 4.32 | 90.2 | 164.0 | 6.46 | 119.6 |
| %CV | 1.3 | 4.1 | 2.5 | 0.8 | 2.3 | 1.1 | 0.7 | 2.1 | 0.9 |
| n | 40 | 40 | 39 | 40 | 40 | 40 | 40 | 40 | 40 |
Serum
| | Na+ | K+ | Cl- | Na+ | K+ | Cl- | Na+ | Cl- |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mean | 113.5 | 2.65 | 48.7 | 117.2 | 4.00 | 91.6 | 144.6 | 132.1 |
| %CV | 1.8 | 2.5 | 2.5 | 0.9 | 1.5 | 1.2 | 0.4 | 0.6 |
| n | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 |
Plasma
| | K+ | Cl- | Na+ | K+ | Cl- | Na+ | K+ | Cl- |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mean | 1.8 | 53.5 | 140.5 | 3.85 | 81.1 | 162.5 | 6.61 | 114.8 |
| %CV | 1.5 | 1.5 | 0.9 | 1.2 | 1.4 | 1.0 | 2.4 | 1.1 |
| n | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 |
Urine
| | Na+ | K+ | Cl- | Na+ | K+ | Cl- | Na+ | K+ | Cl- |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mean | 30.1 | 41.79 | 55.9 | 60.1 | 30.4 | 80.2 | 176.1 | 101.9 | 160.6 |
| %CV | 2.2 | 1.2 | 2.7 | 1.6 | 2.5 | 1.83 | 1.31 | 2.90 | 1.8 |
| n | 39 | 39 | 39 | 40 | 40 | 40 | 40 | 40 | 40 |
## b. Linearity/assay reportable range:
Linearity was evaluated by preparing stock solutions with high concentrations of $\mathrm{Na+}$ , $\mathrm{K+}$ , and $\mathrm{Cl-}$ in whole blood, plasma, serum, and urine. These stocks were diluted to concentrations across the measuring ranges of each analyte and matrix. Linear regression was performed on the results using expected values based on the stock sample dilution. The reportable ranges claimed for whole blood, serum, and plasma are $45 - 210\mathrm{mmol / L}$ for sodium and chloride and $1.5 - 12\mathrm{mmol / L}$ for potassium. The reportable ranges claimed for urine are $30 - 1020\mathrm{mmol / L}$ for sodium, $20 - 505\mathrm{mmol / L}$ for potassium, and $25 - 506\mathrm{mmol / L}$ for chloride. The results are shown below.
Whole Blood
| Parameter | Slope | Intercept | R2 | Conc. Tested | Measuring Range |
| --- | --- | --- | --- | --- | --- |
| Sodium | 1.04 | -10.99 | 0.999 | 13 – 244 | 45-210 |
| Potassium | 1.02 | -0.29 | 0.998 | 1.4 – 37 | 1.5-12 |
| Chloride | 1.04 | -4.32 | 0.998 | 17- 239 | 45-210 |
Plasma
| Parameter | Slope | Intercept | R2 | Conc. Tested | Measuring Range |
| --- | --- | --- | --- | --- | --- |
| Sodium | 1.03 | -11.92 | 0.995 | 35-247 | 45-210 |
| Potassium | 1.00 | 0.04 | 0.999 | 1.4 – 15 | 1.5-12 |
| Chloride | 1.02 | -6.72 | 0.999 | 30-230 | 45-210 |
{5}
6
Serum
| Parameter | Slope | Intercept | R2 | Conc. Tested | Measuring Range |
| --- | --- | --- | --- | --- | --- |
| Sodium | 0.99 | 2.67 | 0.999 | 48 – 250 | 45-210 |
| Potassium | 0.98 | 0.44 | 0.998 | 1.5 – 14.5 | 1.5-12 |
| Chloride | 1.05 | -12.10 | 1.000 | 26-216 | 45-210 |
Urine
| Parameter | Slope | Intercept | R2 | Conc. Tested | Measuring Range |
| --- | --- | --- | --- | --- | --- |
| Sodium | 1.00 | -3.1 | 0.999 | 25 – 1055 | 30-1020 |
| Potassium | 1.00 | 5.5 | 0.999 | 18 – 530 | 20-505 |
| Chloride | 1.02 | -8.4 | 0.999 | 30- 920 | 25-506 |
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
Calibrators were previously cleared under k031159.
d. Detection limit:
Reportable ranges were determined based on the linearity studies (see above).
e. Analytical specificity:
Plasma samples were prepared with high and low concentrations of sodium (129 and 151 mmol/L), potassium (3 and 5.7 mmol/L), and chloride (84 and 115 mmol/L). Interferents were added to these samples and tested. The results were compared to sodium, potassium, and chloride samples without interferent. No interference was defined by the sponsor as a difference of <2 mmol/L for sodium, <0.25 mmol/L for potassium, and <2.8 mmol/L for chloride. The following compounds did not interfere with the results: Salicylic acid at 5 mM, Bilirubin at 500 uM, Triglycerides at 30 mM, Lithium at 3.2 mM, and 40% hematocrit. Albumin, Bromide, and Thiocyanate did cause interference at the concentrations shown below.
| Interferent | Concentration |
| --- | --- |
| Bromide | 3 mmol/L |
| Thiocyanate | 2 mmol/L |
| Albumin | 20 g/L |
f. Assay cut-off:
No Applicable
2. Comparison studies:
a. Method comparison with predicate device:
{6}
Method comparisons to predicate devices were performed with whole blood, plasma, serum and urine patient samples. A small number of samples were spiked or diluted to fully span the claimed measuring ranges. The results are summarized below.
| | Whole Blood | | | | |
| --- | --- | --- | --- | --- | --- |
| | slope | intercept | R² | n | conc. tested |
| Sodium | 1.04 | -3.67 | .985 | 55 | 46.7-204.8 |
| Potassium | 0.91 | 0.44 | .981 | 58 | 1.59-10.14 |
| Chloride | 1.01 | -1.11 | .987 | 57 | 47.8-201.4 |
| | Plasma | | | | |
| | slope | intercept | R² | n | conc. tested |
| Sodium | 1.06 | -8.33 | .991 | 46 | 46.8-205.5 |
| Potassium | 0.97 | 0.15 | .007 | 44 | 1.58-10.99 |
| Chloride | 1.02 | -3.45 | .987 | 47 | 49.3-193.4 |
| | Serum | | | | |
| | slope | intercept | R² | N | conc. tested |
| Sodium | 1.07 | -8.41 | .992 | 69 | 48.7-205.4 |
| Potassium | 0.90 | 0.44 | .995 | 65 | 1.70-10.26 |
| Chloride | 1.08 | -8.82 | .988 | 64 | 48.9-199.1 |
| | Urine | | | | |
| | slope | intercept | R² | n | conc. tested |
| Sodium | 1.07 | -9.15 | 0.999 | 43 | 34.5-1012 |
| Potassium | 1.04 | -3.91 | 0.996 | 42 | 21.9-503.1 |
| Chloride | 1.00 | -8.43 | 0.996 | 42 | 27.9-505.3 |
b. Matrix comparison:
Assay performance in all claimed matrices is addressed in the method comparison studies described above.
3. Clinical studies:
a. Clinical Sensitivity: Not Applicable
b. Clinical specificity: Not Applicable
c. Other clinical supportive data (when a. and b. are not applicable): Not Applicable
4. Clinical cut-off:
{7}
Not applicable
5. Expected values/Reference range:
The value given in the tables below are intended to be used only as a guide. Each laboratory or testing site should establish its own range of normal values, taking into account factors such as age, sex, diet, and other determinants of electrolyte levels.
Whole Blood, Serum, Plasma (mmol/L or mEq/L)
Sodium (Na+) 135 to 148
Potassium (K+) 3.5 to 5.3
Chloride (Cl-) 98 to 107
Urine (mmoL/L or mEq/L) spot
Sodium (Na+) 40 to 220
Potassium (K+) 25 to 120
Chloride (Cl-) 110 to 250
1 Tietz, N.W. (ed.) Fundamentals of Clinical Chemistry, 2nd ed. (1976), p. 875-77
2 Geige Scientific Tables, Vol. 3, 8th edition
N. Instrument Name:
Diamond Diagnostics proLYTE Electrolyte Analyzer
O. System Descriptions:
1. Modes of Operation:
Fully automated with 'Yes' or 'No' commands for menu navigation.
2. Software:
FDA has reviewed applicant's Hazard Analysis and software development processes for this line of product types:
Yes ☐ X or No ☐
3. Specimen Identification:
{8}
Manual
4. Specimen Sampling and Handling:
Samples are manually placed on the instrument one at a time, tested, and removed.
5. Calibration:
One point automated on board calibration performed every four hours or upon request. The slope is calculated during calibration and stored for sample measurement.
6. Quality Control:
Controls are run manually and recommended daily. Results can be stored in instrument memory for future use.
P. Other Supportive Instrument Performance Characteristics Data Not Covered In The "Performance Characteristics" Section above:
Not applicable
Q. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
R. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
9